Development process of Laihe Biotech


Hangzhou Laihe Biotech Co., Ltd was founded and won the key support project of Hangzhou Binjiang 5050 Overseas High-level Talents innovation and Entrepreneurship: In November of the same year, we obtained the medical device production license.

In 2012

Approved by ISO13485 and CE, Laihe Biotech starts the international business.

In 2015

Laihe obtained seven patents,and the Drugs of Abuse Test was shortlisted in the National Ministry of Public Security's anti-drug recommended catalog.

In 2016

6 ClassⅢmedical devices are certificated and listed on the market. Laihe has awarded the National High-tech Enterprise Certificate.

In 2017

Laihe rated as AAA-level quality-oriented and trustworthy enterprise.

In 2019

Laihe contribute to the fight against the novel coronavirus pandemic. The company and the general manager personally donated nearly 100,000 yuan to Wuhan Charity Federation Hangzhou High-tech Zone Red Cross Society and other organizations. About 100,000 kits have been donated to medical institutions in the Lombard Region of Italy, the local Chinese Chamber of Commerce in Spain,the Pakistani Embassy in China, the Aube Province of France theGovernment of Peru, the Embassy of Zimbabwe, the Embassy of Georgia, and the Embassy of Moldova. Laihe obtained international certifications such as US FDA EUA,German BfArM,French ANSM. Australian TGA, etc.

In 2020

Laihe passed the Ministry of Public Security drug hair detection evaluation, and was shortlisted in the supplier directory Laihe hold 8 international and national invention patents,10 new-type patents,10 appearance patents,5 software registration rights.

In August 2020

The products are popular in more than 40 countries and regions all around the world, and have obtained the "LYHER" brand trademark in 18 major countries and regions including the EU USA,Brazil, Japan, South Africa, Russia, etc., and registration certificates of competent authorities in many countries.

In 2021